The FDA approved Bristol Myers Squibb's Zenbexus (iberdomide) plus daratumumab and dexamethasone for relapsed or refractory multiple myeloma, marking the first

Eli Lilly is suing multiple firms for allegedly selling unapproved versions of retatrutide, a highly anticipated experimental obesity drug, on the black market.

Lilly alleges six companies illegally sold unapproved versions of its experimental obesity drug retatrutide through black-market channels.

Prescription drug prices have fallen more steeply than at any point in over six decades, with the Trump administration attributing the decline to its drug prici

Replimune received FDA accelerated approval for its melanoma treatment TUDRIQEV, raised roughly $141-150 million, and is rebuilding its commercial team with a l

Capricor Therapeutics shares surged after the company announced plans to amend its FDA filing for its Duchenne muscular dystrophy therapy following a prior advi

The FDA approved Moderna's mRNA-based influenza vaccine, though the company does not expect material revenue from the product until 2027 as market adoption buil

Novo Nordisk's CEO stated the obesity drug market is not a zero-sum game and said patients are seeking optionality among treatments, as competition with Eli Lil

Eledon Pharmaceuticals reported that all 12 patients in its islet cell transplant study achieved insulin independence, a potential breakthrough for type 1 diabe

Novo Nordisk has filed a lawsuit against a rival company over advertising claims related to obesity drugs.

A new survey reveals that US biotech companies strongly prefer conducting first-in-human trials domestically, but regulatory hurdles at the FDA are increasingly

Novo Nordisk shares declined following a Berenberg downgrade citing concerns over the company's guidance and increasing competition in the obesity drug market.

Major pharmacy benefit managers have agreed to provide TrumpRx drug pricing information to their members, advancing transparency in prescription drug costs.

Senator Elizabeth Warren is pressing HHS Secretary Robert F. Kennedy Jr. to make public the negotiated drug pricing deals under the TrumpRx program, questioning

Novo Nordisk's oral formulation of Wegovy is facing challenges in gaining significant market share, despite being a highly anticipated product in the obesity sp

Government subsidies for weight-loss medications could cost the federal budget up to $10 billion as demand for GLP-1 drugs surges.

Quantum BioPharma received FDA clearance to begin a Phase 2 trial for its multiple sclerosis drug Lucid-MS, while also reporting Q2 results showing reduced oper

Pharmaceutical companies are reducing reimbursement applications in Switzerland due to concerns that Swiss pricing could set precedents for US drug price negoti